Navigation Links
ACTUS Appoints New Members to Its Management Team
Date:10/1/2013

Oro Valley, AZ (PRWEB) October 01, 2013

ACTUS Biotechnologies has recently added four highly experienced industry professionals to its management team, further broadening the capabilities of its existing team, and adding more than a century of experience to the organization. The ACTUS Biotechnologies management team serves in a duplicate role in each of the accelerator’s subsidiaries, Convoy Therapeutics and EnduRx Pharmaceuticals. These personnel round out a team that already includes executive and senior management in Regulatory Affairs, Quality Assurance, and Business Development.

Dr. Deborah Slee has joined ACTUS as the Vice President of Research & Development, overseeing a team of fifteen personnel from various disciplines serving in full-time and consulting capacities within the organization. She is also leading efforts at the ACTUS laboratory being established at the Janseen incubator in La Jolla, CA. Dr. Slee’s career includes more than twenty years of industry experience in a variety of therapeutic areas leading development efforts. She is a co-founder of both Aspyrian Therapeutics and CendR Therapeutics and previously led efforts at both Ontogen and Neurocrine Biosciences. Dr. Slee received her Ph.D. from the University of Exeter and performed post-doctoral research at The Scripps Research Institute in La Jolla, CA.

Also joining the ACTUS Research & Development team is Dr. Sarah Hudson, as the Director of Project Management. With more than ten years of experience in research and development and project management in biopharmaceutical companies, including Neurocrine Biosciences, Exelixis, and most recently CovX, a division of Pfizer, she brings an outstanding track record to the ACTUS team. Dr. Hudson earned her Ph.D. at the University of Bristol and performed her post-doctoral work at Neurocrine Biosciences.

Mr. Brandon French, an accomplished healthcare operations and business development professional, has joined ACTUS as its Vice President of Operations. His experience includes more than twenty years in healthcare real estate and financial management. Mr. French earned his B.S. in Finance from the Minder School of Business at Oklahoma City University.

ACTUS Biotechnologies has added Ms. Tanya Paschke as their new Director of Operations. Ms. Paschke’s career includes more than 25 years of experience in the biopharmaceutical industry with roles of increasing responsibility in operational management of facilities, core research and development efforts and sales and marketing in major pharmaceutical and academic institutions.

About ACTUS Biotechnologies

ACTUS Biotechnologies is an accelerator company, commercializing the most impactful biopharmaceutical technologies; bridging the gap between academic research and industrial commercialization. The ACTUS Biotechnologies management team includes an exceptional team of individuals with decades of expertise in all aspects of the Life Sciences business sector. The team’s singular mission is the rapid growth and commercialization of technologies that have the potential to positively impact both the practice of medicine and patient quality of life; driven by innovation, forward thinking, integrity and empowerment.

During its licensing process, the ACTUS team performs extensive review and due diligence, ensuring the technology meets ACTUS’ standard of excellence. Licensed technologies are spun off into new, wholly-owned subsidiaries and provided with initial capital, and all operational support required to accelerate commercialization including: Operations, Research & Development, Project Planning, Business Development, and Legal. Current subsidiaries within the accelerator include Convoy Therapeutics (http://www.convoytx.com) and EnduRx Pharmaceuticals (http://www.endurxpharma.com).

Read the full story at http://www.prweb.com/releases/2013/10/prweb11180794.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Immune Design Appoints Stephen R. Brady Chief Business Officer
2. DiaVacs, Inc. Appoints Orville Kolterman, M.D. As Chief Medical Officer
3. Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
4. Solulink Appoints Life Science Industry Veteran Jack Ball as Chief Executive Officer
5. Cold Spring Harbor Laboratory Appoints Teri F. Willey to Accelerate Commercialization Efforts
6. Senn Chemicals Appoints New Chief Executive Officer
7. Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
8. Creabilis Appoints Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board
9. Alexander Proudfoot Appoints Executive Vice President for Life Sciences
10. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
11. KaloBios Appoints Donald R. Joseph as Chief Legal Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... CAMBRIDGE, Mass. , Jan. 18, 2017   ... of novel compounds designed to target cancer stemness pathways, ... lead investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal ... San Francisco . Napabucasin is ... pathways by targeting STAT3. i Cancer stem cells ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and Sports ... A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at Long ... an anterior cervical discectomy and fusion on a 42 year old female who ...
(Date:1/18/2017)... ... ... from a new study are stating that if levels of the blood test called ... there is still remaining prostate cancer cells that are more likely to come back, spreading ... an indicator of whether a man’s prostate cancer is growing or not,” stated Dr. ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Thirty-six startup companies ... credits by the Pennsylvania Department of Community and Economic Development in 2016 as part ... located in the University City Keystone Innovation Zone and represent the highest number of ...
Breaking Biology Technology:
(Date:1/3/2017)... LAS VEGAS , Jan. 3, 2017 ... announced the introduction of Onitor Track, an innovative biometric ... and men, showcasing this month at the 2017 Consumer ... . In the U.S., the World ... affect more than two-thirds of adults who are overweight ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
Breaking Biology News(10 mins):